An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population

An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population

In September 2023, 10-valent pneumococcal conjugate vaccine (PCV) was replaced by 15-valent PCV (PCV15) in Sweden’s pediatric national immunization program. Following European approval of 20-valent PCV (PCV20) in March 2024, we assessed the cost-effectiveness of PCV20 versus PCV15, both under 2 + 1...

Full description

Saved in:
Bibliographic Details
Main Authors: Ann-Charlotte Fridh, Andreas Palmborg, An Ta, Donata Freigofaite, Sophie Warren, Johnna Perdrizet
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Pneumococcal disease
cost-effectiveness
pneumococcal conjugate vaccination
pediatric
pneumonia
invasive pneumococcal disease
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2400751
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items